Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
$46.96
-$0.17(-0.45%)
At close: 4:00 PM EST
$46.96
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$36.22 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)5.15M
Market Cap
$8.40B
Enterprise Value$8.37B
Total Cash (Recent Filing)$755.00M
Total Debt (Recent Filing)$815.71M
Price to Earnings (P/E)―
Beta3.10
Next Earnings
May 12, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding173,729,900
10 Day Avg. Volume4,425,298
30 Day Avg. Volume5,147,150
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.58
Enterprise Value/Gross Profit9.45
Enterprise Value/Ebitda-37.64
Forecast
1Y Price Target
$78.69Price Target Upside67.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$1.59B
Bulls Say, Bears Say
Bulls Say
Diagnostic Product Portfolio And Clinical Workflow IntegrationIntegration of cleared artificial intelligence lung cancer detection into the imaging platform and a comprehensive diagnostics suite covering hereditary testing, therapy selection, and minimal residual disease testing can boost clinician adoption and increase test volumes.
Pricing And Revenue Mix Improvement From Product MigrationMigration to newer regulatory-cleared diagnostic platforms and scaling of higher-priced assays alongside rising oncology testing volumes can raise average selling prices and strengthen diagnostic revenue growth.
Strategic Partnerships And Data ContractsExpanded multi-year collaborations and large pharmaceutical deals for curated, de-identified datasets and the Lens platform can drive recurring data revenue and validate the company's role as a supplier of research insights for drug development.
Bears Say
Competitive And Contract Renewal RisksIntense competition in genomics, persistent pricing pressure, and investor concern about the likelihood of contract renewals for multimodal datasets raise execution risks that could slow data business growth and weigh on valuation.
Profitability And Expense PressureOngoing net losses paired with higher planned operating expenses and adjusted profitability below expectations increase margin pressure and heighten the risk of weaker near-term earnings.
Reimbursement UncertaintyBeing early in the reimbursement journey creates uncertainty about revenue realization from diagnostic tests and may delay expected improvements in cash flow and revenue visibility.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $36.22 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $8.40B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is May 12, 2026 which is in 50 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Feb 24, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.033 by -$0.007.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.19.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 173,729,900 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.033. Following the earnings report the stock price went down -7.317%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.69 (67.57% Upside)
$78.69 (67.57% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 73%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 233.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.24%
12-Months-Change
Fundamentals
Return on Equity
-59.95%
Trailing 12-Months
Asset Growth
145.63%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized robust multi-year growth drivers: strong diagnostic unit growth (Oncology +29%, MRD +56% Q/Q), accelerating data business with >$1.1B in TCV and 126% net revenue retention, positive 2026 guidance ($1.59B) and a path to higher ASPs and adjusted EBITDA. Key near-term constraints are reimbursement gating for MRD, moderation and lumpiness in Hereditary growth, and one-time impacts to some reported data growth figures. Overall, the positive revenue, contract backlog, AI/foundation-model progress, and strong customer retention materially outweigh the execution and reimbursement risks highlighted.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$78.69
▲(67.57% Upside)
Technical Analysis
Ownership Overview
22.93% Insiders
8.88% Mutual Funds
27.24% Other Institutional Investors
25.92% Public Companies and Individual Investors